Opioids and matrix metalloproteinases: the influence of morphine on MMP-9 production and cancer progression.
MMP-9
Matrix metalloproteinases
Morphine
NF-κB
Nitric oxide
Opioids
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
07
11
2018
accepted:
09
01
2019
pubmed:
19
1
2019
medline:
25
12
2019
entrez:
19
1
2019
Statut:
ppublish
Résumé
Opioids are widely administered to alleviate pain, including chronic pain in advanced cancer patients. Among opioids, morphine is one of the most clinically effective drugs for the palliative management of severe pain. In the last few decades, there has been a debate around the possible influence of opioids such as morphine on tumour growth and metastasis. Whilst several in vitro and in vivo studies suggest the possible modulatory effects of morphine on tumour cells, little is known about the impact of this analgesic drug on other mediators such as matrix metalloproteinases (MMPs) that play a key role in the control of cancer cell invasion and metastasis. MMP-9 has been considered as one of the principal mediators in regulation of not only the initial steps of cancer but during the invasion and spreading of cancer cells to distant organs. Herein, current studies regarding the direct and indirect effects of morphine on regulation of MMP-9 production are discussed. In addition, drawing from previous in vivo and in vitro studies on morphine action in regulating MMP-9 production, the potential roles of several underlying factors are summarised, including nuclear factor kappa-B and intracellular molecules such as nitric oxide.
Identifiants
pubmed: 30656360
doi: 10.1007/s00210-019-01613-6
pii: 10.1007/s00210-019-01613-6
doi:
Substances chimiques
Analgesics, Opioid
0
NF-kappa B
0
Nitric Oxide
31C4KY9ESH
Morphine
76I7G6D29C
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
123-133Subventions
Organisme : National Health and Medical Research Council
ID : 0508046
Pays : International
Organisme : National Health and Medical Research Council
ID : 0508047
Pays : International
Organisme : National Health and Medical Research Council
ID : 1042105
Pays : International
Références
Afsharimani B, Cabot P, Parat MO (2011a) Morphine and tumor growth and metastasis. Cancer Metastasis Rev 30:225–238
doi: 10.1007/s10555-011-9285-0
pubmed: 21267766
Afsharimani B, Cabot PJ, Parat MO (2011b) Morphine use in cancer surgery. Front Pharmacol 2:46
doi: 10.3389/fphar.2011.00046
pubmed: 21852973
pmcid: 3151591
Afsharimani B, Baran J, Watanabe S, Lindner D, Cabot PJ, Parat MO (2014) Morphine and breast tumor metastasis: the role of matrix-degrading enzymes. Clin Exp Metastasis 31:149–158
doi: 10.1007/s10585-013-9616-3
pubmed: 24072419
Azuma Y, Ohura K (2002) Endomorphins 1 and 2 inhibit IL-10 and IL-12 production and innate immune functions, and potentiate NF-kappaB DNA binding in THP-1 differentiated to macrophage-like cells. Scand J Immunol 56:260–269
doi: 10.1046/j.1365-3083.2002.01128.x
pubmed: 12193227
Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141–179
doi: 10.1146/annurev.iy.12.040194.001041
pubmed: 8011280
Beltran JA, Peek J, Chang SL (2006) Expression and regulation of the mu opioid peptide receptor in TPA-differentiated HL-60 promyelocytic leukemia cells. Int Immunopharmacol 6:1331–1340
doi: 10.1016/j.intimp.2006.03.017
pubmed: 16782547
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744
doi: 10.1038/35036374
pubmed: 2852586
pmcid: 2852586
Bilfinger TV, Hartman AR, Liu Y, Magazine HI, Stefano GB (1997) Cryopreserved veins in myocardial revascularization: possible mechanism for their increased failure. Ann Thorac Surg 63:1063–1069
doi: 10.1016/S0003-4975(97)00167-7
pubmed: 9124906
Bilfinger TV, Fimiani C, Stefano GB (1998) Morphine's immunoregulatory actions are not shared by fentanyl. Int J Cardiol 64(Suppl 1):S61–S66
doi: 10.1016/S0167-5273(98)00037-0
pubmed: 9687094
Bimonte S, Barbieri A, Palma G, Arra C (2013) The role of morphine in animal models of human cancer: does morphine promote or inhibit the tumor growth? Biomed Res Int 2013:258141
pubmed: 24069592
pmcid: 3771243
Borner C, Kraus J (2013) Inhibition of NF-kappaB by opioids in T cells. J Immunol 191:4640–4647
doi: 10.4049/jimmunol.1300320
pubmed: 24068670
Borner C, Hollt V, Kraus J (2012) Mechanisms of the inhibition of nuclear factor-kappa B by morphine in neuronal cells. Mol Pharmacol 81:587–597
doi: 10.1124/mol.111.076620
pubmed: 22258905
Bove PF, Wesley UV, Greul AK, Hristova M, Dostmann WR, van der Vliet A (2007) Nitric oxide promotes airway epithelial wound repair through enhanced activation of MMP-9. Am J Respir Cell Mol Biol 36:138–146
doi: 10.1165/rcmb.2006-0253SM
pubmed: 16980554
Brunet A, Datta SR, Greenberg ME (2001) Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 11:297–305
doi: 10.1016/S0959-4388(00)00211-7
pubmed: 11399427
Cadet P, Rasmussen M, Zhu W, Tonnesen E, Mantione KJ, Stefano GB (2004) Endogenous morphinergic signaling and tumor growth. Front Biosci 9:3176–3186
doi: 10.2741/1471
pubmed: 15353348
Carr DJ, Carpenter GW, Garza HH Jr, France CP, Prakash OM (1995) Chronic & infrequent opioid exposure suppresses IL-2R expression on rhesus monkey peripheral blood mononuclear cells following stimulation with pokeweed mitogen. Int J Neurosci 81:137–148
doi: 10.3109/00207459509015305
pubmed: 7775068
Charbaji N, Rosenthal P, Schafer-Korting M, Kuchler S (2013) Cytoprotective effects of opioids on irradiated oral epithelial cells. Wound Repair Regen 21:883–889
doi: 10.1111/wrr.12115
pubmed: 24134439
Chen HH, Wang DL (2004) Nitric oxide inhibits matrix metalloproteinase-2 expression via the induction of activating transcription factor 3 in endothelial cells. Mol Pharmacol 65:1130–1140
doi: 10.1124/mol.65.5.1130
pubmed: 15102941
Chen Y, Mestek A, Liu J, Yu L (1993) Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem J 295(Pt 3):625–628
doi: 10.1042/bj2950625
pubmed: 8240267
pmcid: 1134603
Colasanti M, Persichini T, Menegazzi M, Mariotto S, Giordano E, Caldarera CM, Sogos V, Lauro GM, Suzuki H (1995) Induction of nitric oxide synthase mRNA expression. Suppression by exogenous nitric oxide. J Biol Chem 270:26731–26733
doi: 10.1074/jbc.270.45.26731
pubmed: 7592903
Coussens LM, Werb Z (1996) Matrix metalloproteinases and the development of cancer. Chem Biol 3:895–904
doi: 10.1016/S1074-5521(96)90178-7
pubmed: 8939708
Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481–490
doi: 10.1016/S0092-8674(00)00139-2
pubmed: 11081634
pmcid: 2843102
Cox BM, Christie MJ, Devi L, Toll L, Traynor JR (2015) Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br J Pharmacol 172:317–323
doi: 10.1111/bph.12612
pubmed: 24528283
Dahl KDC, Zeineldin R, Hudson LG (2007) PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res 5:413–421
doi: 10.1158/1541-7786.MCR-07-0019
de Launoit Y, Baert JL, Chotteau-Lelievre A, Monte D, Coutte L, Mauen S, Firlej V, Degerny C, Verreman K (2006) The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta 1766:79–87
pubmed: 16546322
Drouet C, Shakhov AN, Jongeneel CV (1991) Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-alpha promoter in primary macrophages. J Immunol 147:1694–1700
pubmed: 1715367
Duffy MJ (2004) The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10:39–49
doi: 10.2174/1381612043453559
pubmed: 14754404
Eberhardt W, Beeg T, Beck KF, Walpen S, Gauer S, Bohles H, Pfeilschifter J (2000a) Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. Kidney Int 57:59–69
doi: 10.1046/j.1523-1755.2000.00808.x
pubmed: 10620188
Eberhardt W, Huwiler A, Beck KF, Walpen S, Pfeilschifter J (2000b) Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J Immunol 165:5788–5797
doi: 10.4049/jimmunol.165.10.5788
pubmed: 11067938
Engbring JA, Kleinman HK (2003) The basement membrane matrix in malignancy. J Pathol 200:465–470
doi: 10.1002/path.1396
pubmed: 12845613
Esteve PO, Chicoine E, Robledo O, Aoudjit F, Descoteaux A, Potworowski EF, St-Pierre Y (2002) Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in glioma cells via NF-kappa B. J Biol Chem 277:35150–35155
doi: 10.1074/jbc.M108600200
pubmed: 12130632
Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH (1992) Cloning of a delta opioid receptor by functional expression. Science 258:1952–1955
doi: 10.1126/science.1335167
pubmed: 1335167
Fimiani C, Arcuri E, Santoni A, Rialas CM, Bilfinger TV, Peter D, Salzet B, Stefano GB (1999) Mu3 opiate receptor expression in lung and lung carcinoma: ligand binding and coupling to nitric oxide release. Cancer Lett 146:45–51
doi: 10.1016/S0304-3835(99)00227-X
pubmed: 10656608
Fukuda K, Kato S, Mori K, Nishi M, Takeshima H (1993) Primary structures and expression from cDNAs of rat opioid receptor delta- and mu-subtypes. FEBS Lett 327:311–314
doi: 10.1016/0014-5793(93)81011-N
pubmed: 8394245
Fukuda K, Kato S, Morikawa H, Shoda T, Mori K (1996) Functional coupling of the delta-, mu-, and kappa-opioid receptors to mitogen-activated protein kinase and arachidonate release in Chinese hamster ovary cells. J Neurochem 67:1309–1316
doi: 10.1046/j.1471-4159.1996.67031309.x
pubmed: 8752140
Gach K, Szemraj J, Wyrebska A, Janecka A (2011a) The influence of opioids on matrix metalloproteinase-2 and -9 secretion and mRNA levels in MCF-7 breast cancer cell line. Mol Biol Rep 38:1231–1236
doi: 10.1007/s11033-010-0222-z
pubmed: 20563853
Gach K, Wyrebska A, Fichna J, Janecka A (2011b) The role of morphine in regulation of cancer cell growth. Naunyn Schmiedeberg's Arch Pharmacol 384:221–230
doi: 10.1007/s00210-011-0672-4
Gach K, Wyrebska A, Szemraj J, Janecka A (2012) The influence of opioid peptides on matrix metalloproteinase-9 and urokinase plasminogen activator expression in three cancer cell lines. Mol Biol 46:894–899
doi: 10.1134/S0026893312060052
Gordon GM, Ledee DR, Feuer WJ, Fini ME (2009) Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells. J Cell Physiol 221:402–411
doi: 10.1002/jcp.21869
pubmed: 19626678
pmcid: 2990951
Gurjar MV, DeLeon J, Sharma RV, Bhalla RC (2001) Mechanism of inhibition of matrix metalloproteinase-9 induction by NO in vascular smooth muscle cells. J Appl Physiol (1985) 91:1380–1386
doi: 10.1152/jappl.2001.91.3.1380
Hamada T, Duarte S, Tsuchihashi S, Busuttil RW, Coito AJ (2009) Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury. Am J Pathol 174:2265–2277
doi: 10.2353/ajpath.2009.080872
pubmed: 19443702
pmcid: 2684191
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
doi: 10.1016/S0092-8674(00)81683-9
pubmed: 10647931
pmcid: 10647931
Handal M, Grung M, Skurtveit S, Ripel A, Morland J (2002) Pharmacokinetic differences of morphine and morphine-glucuronides are reflected in locomotor activity. Pharmacol Biochem Behav 73:883–892
doi: 10.1016/S0091-3057(02)00925-5
pubmed: 12213535
Harimaya Y, Koizumi K, Andoh T, Nojima H, Kuraishi Y, Saiki I (2002) Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett 187:121–127
doi: 10.1016/S0304-3835(02)00360-9
pubmed: 12359359
Henry DJ, Grandy DK, Lester HA, Davidson N, Chavkin C (1995) Kappa-opioid receptors couple to inwardly rectifying potassium channels when coexpressed by Xenopus oocytes. Mol Pharmacol 47:551–557
pubmed: 7700253
Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ (2002) Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 94:1134–1142
doi: 10.1093/jnci/94.15.1134
pubmed: 12165638
Huang Y, Lu MQ, Li H, Xu C, Yi SH, Chen GH (2006) Occurrence of cGMP/nitric oxide-sensitive store-operated calcium entry in fibroblasts and its effect on matrix metalloproteinase secretion. World J Gastroenterol 12:5483–5489
doi: 10.3748/wjg.v12.i34.5483
pubmed: 17006985
pmcid: 4088230
Hutchinson MR, Zhang YN, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR (2010) Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 24:83–95
doi: 10.1016/j.bbi.2009.08.004
pubmed: 19679181
Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR (2011) Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev 63:772–810
doi: 10.1124/pr.110.004135
pubmed: 21752874
pmcid: 3141878
Hutchinson MR, Northcutt AL, Hiranita T, Wang X, Lewis SS, Thomas J, van Steeg K, Kopajtic TA, Loram LC, Sfregola C, Galer E, Miles NE, Bland ST, Amat J, Rozeske RR, Maslanik T, Chapman TR, Strand KA, Fleshner M, Bachtell RK, Somogyi AA, Yin H, Katz JL, Rice KC, Maier SF, Watkins LR (2012) Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci 32:11187–11200
doi: 10.1523/JNEUROSCI.0684-12.2012
pubmed: 22895704
pmcid: 3454463
Jespersen C, Doller A, Akool el S, Bachmann M, Muller R, Gutwein P, Muhl H, Pfeilschifter J, Eberhardt W (2009) Molecular mechanisms of nitric oxide-dependent inhibition of TPA-induced matrix metalloproteinase-9 (MMP-9) in MCF-7 cells. J Cell Physiol 219:276–287
doi: 10.1002/jcp.21658
pubmed: 19130490
Katsuyama K, Shichiri M, Marumo F, Hirata Y (1998) NO inhibits cytokine-induced iNOS expression and NF-kappa B activation by interfering with phosphorylation and degradation of I kappa B-alpha. Arterioscler Thromb Vasc Biol 18:1796–1802
doi: 10.1161/01.ATV.18.11.1796
pubmed: 9812920
Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52–67
doi: 10.1016/j.cell.2010.03.015
pubmed: 2862057
pmcid: 2862057
Khabbazi S, Goumon Y, Parat MO (2015) Morphine modulates Interleukin-4-or breast cancer cell-induced pro-metastatic activation of macrophages. Sci Rep 5:11389
doi: 10.1038/srep11389
pubmed: 26078009
pmcid: 4468425
Khabbazi S, Xie N, Pu WJ, Goumon Y, Parat MO (2016) The TLR4-active morphine metabolite morphine-3-glucuronide does not elicit macrophage classical activation in vitro. Front Pharmacol 7:441
Kieffer BL, Gaveriaux-Ruff C (2002) Exploring the opioid system by gene knockout. Prog Neurobiol 66:285–306
doi: 10.1016/S0301-0082(02)00008-4
pubmed: 12015197
Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J (2009) Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 9:188
doi: 10.1186/1471-2407-9-188
pubmed: 19531263
pmcid: 2706257
Kondraganti S, Mohanam S, Chintala SK, Kin Y, Jasti SL, Nirmala C, Lakka SS, Adachi Y, Kyritsis AP, Ali-Osman F, Sawaya R, Fuller GN, Rao JS (2000) Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 60:6851–6855
pubmed: 11156378
Koodie L, Ramakrishnan S, Roy S (2010) Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway. Am J Pathol 177:984–997
doi: 10.2353/ajpath.2010.090621
pubmed: 20616349
pmcid: 2913371
Koodie L, Yuan H, Pumper JA, Yu H, Charboneau R, Ramkrishnan S, Roy S (2014) Morphine inhibits migration of tumor-infiltrating leukocytes and suppresses angiogenesis associated with tumor growth in mice. Am J Pathol 184:1073–1084
doi: 10.1016/j.ajpath.2013.12.019
pubmed: 24495739
pmcid: 3969995
Kraus J, Borner C, Giannini E, Hollt V (2003) The role of nuclear factor kappaB in tumor necrosis factor-regulated transcription of the human mu-opioid receptor gene. Mol Pharmacol 64:876–884
doi: 10.1124/mol.64.4.876
pubmed: 14500744
Kuo CK, Hanioka N, Hoshikawa Y, Oguri K, Yoshimura H (1991) Species difference of site-selective glucuronidation of morphine. Aust J Pharm 14:187–193
Kupatt C, Weber C, Wolf DA, Becker BF, Smith TW, Kelly RA (1997) Nitric oxide attenuates reoxygenation-induced ICAM-1 expression in coronary microvascular endothelium: role of NFkappaB. J Mol Cell Cardiol 29:2599–2609
doi: 10.1006/jmcc.1997.0439
pubmed: 9344755
Labrie M, St-Pierre Y (2013) Epigenetic regulation of mmp-9 gene expression. Cell Mol Life Sci 70:3109–3124
doi: 10.1007/s00018-012-1214-z
pubmed: 23184252
Law PY, Wong YH, Loh HH (2000) Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 40:389–430
doi: 10.1146/annurev.pharmtox.40.1.389
pubmed: 10836142
Law PY, Loh HH, Wei LN (2004) Insights into the receptor transcription and signaling: implications in opioid tolerance and dependence. Neuropharmacology 47(Suppl 1):300–311
doi: 10.1016/j.neuropharm.2004.07.013
pubmed: 15464146
Lee YJ, Suh SY, Song J, Lee SS, Seo AR, Ahn HY, Lee MA, Kim CM, Klepstad P (2015) Serum and urine concentrations of morphine and morphine metabolites in patients with advanced cancer receiving continuous intravenous morphine: an observational study. BMC Palliat Care 14:53
doi: 10.1186/s12904-015-0052-9
pubmed: 26507979
pmcid: 4624671
Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, Singleton PA (2014) The mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and epithelial mesenchymal transition (EMT) in human lung cancer. PLoS One 9:e91577
doi: 10.1371/journal.pone.0091577
pubmed: 24662916
pmcid: 3963855
Lynch CC, Matrisian LM (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation 70:561–573
doi: 10.1046/j.1432-0436.2002.700909.x
pubmed: 12492497
Magazine HI, Liu Y, Bilfinger TV, Fricchione GL, Stefano GB (1996) Morphine-induced conformational changes in human monocytes, granulocytes, and endothelial cells and in invertebrate immunocytes and microglia are mediated by nitric oxide. J Immunol 156:4845–4850
pubmed: 8648133
Marshall HE, Stamler JS (2001) Inhibition of NF-kappa B by S-nitrosylation. Biochemistry 40:1688–1693
doi: 10.1021/bi002239y
pubmed: 11327828
Matthews JR, Botting CH, Panico M, Morris HR, Hay RT (1996) Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res 24:2236–2242
doi: 10.1093/nar/24.12.2236
pubmed: 145924
pmcid: 145924
Mignatti P, Rifkin DB (2000) Nonenzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. Adv Cancer Res 78:103–157
doi: 10.1016/S0065-230X(08)61024-6
pubmed: 10547669
Miyamae T, Fukushima N, Misu Y, Ueda H (1993) Delta opioid receptor mediates phospholipase C activation via Gi in Xenopus oocytes. FEBS Lett 333:311–314
doi: 10.1016/0014-5793(93)80677-M
pubmed: 8224200
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149
doi: 10.1200/JCO.2000.18.5.1135
pubmed: 10694567
Osborne R, Joel S, Trew D, Slevin M (1990) Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 47:12–19
doi: 10.1038/clpt.1990.2
pubmed: 2295214
O'Sullivan S, Medina C, Ledwidge M, Radomski MW, Gilmer JF (2014) Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance--NO and MMP-9 interactions. Biochim Biophys Acta 1843:603–617
doi: 10.1016/j.bbamcr.2013.12.006
pubmed: 24333402
Ozawa T, Nakagawa T, Minami M, Satoh M (1999) Supersensitization of the adenylyl cyclase system in Chinese hamster ovary cells co-expressing cloned opioid receptors and Gz, a PTX-insensitive G protein. Neurosci Lett 267:117–120
doi: 10.1016/S0304-3940(99)00347-X
pubmed: 10400226
Park SK, Lin HL, Murphy S (1997) Nitric oxide regulates nitric oxide synthase-2 gene expression by inhibiting NF-kappaB binding to DNA. Biochem J 322(Pt 2):609–613
doi: 10.1042/bj3220609
pubmed: 9065784
pmcid: 1218233
Peacock J (1999) C. Stein (editor), opioids in pain control—basic and clinical aspects. Br J Anaesth 83:978–979
doi: 10.1093/bja/83.6.978
Peng HB, Libby P, Liao JK (1995) Induction and stabilization of I-kappa-B-alpha by nitric-oxide mediates inhibition of Nf-kappa-B. J Biol Chem 270:14214–14219
doi: 10.1074/jbc.270.23.14214
pubmed: 7775482
Peng HB, Spiecker M, Liao JK (1998) Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. J Immunol 161:1970–1976
pubmed: 9712068
Piros ET, Prather PL, Loh HH, Law PY, Evans CJ, Hales TG (1995) Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells. Mol Pharmacol 47:1041–1049
pubmed: 7746271
Polakiewicz RD, Schieferl SM, Dorner LF, Kansra V, Comb MJ (1998) A mitogen-activated protein kinase pathway is required for mu-opioid receptor desensitization. J Biol Chem 273:12402–12406
doi: 10.1074/jbc.273.20.12402
pubmed: 9575195
Pourshanazari A, Allahtavakoli M, Hassanshahi G (2011) Effects of low-dose morphine on nitric oxide concentration and angiogenesis in two-kidney one clip hypertensive rats. Iran J Basic Med Sci 14:560–567
pubmed: 23493527
pmcid: 3586858
Prevot V, Rialas CM, Croix D, Salzet M, Dupouy JP, Poulain P, Beauvillain JC, Stefano GB (1998) Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: neurovascular regulation. Brain Res 790:236–244
doi: 10.1016/S0006-8993(98)00066-3
pubmed: 9593913
Qin L, Liao L, Redmond A, Young L, Yuan YH, Chen HW, O'Malley BW, Xu JM (2008) The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol 28:5937–5950
doi: 10.1128/MCB.00579-08
pubmed: 18644862
pmcid: 2547002
Qin T, Huang D, Liu Z, Zhang X, Jia Y, Xian CJ, Li K (2018) Tumor necrosis factor superfamily 15 promotes lymphatic metastasis via upregulation of vascular endothelial growth factor-C in a mouse model of lung cancer. Cancer Sci 109:2469–2478
doi: 10.1111/cas.13665
pubmed: 29890027
pmcid: 6113425
Qiu S, Feng Y, LeSage G, Zhang Y, Stuart C, He L, Li Y, Caudle Y, Peng Y, Yin D (2015) Chronic morphine-induced microRNA-124 promotes microglial immunosuppression by modulating P65 and TRAF6. J Immunol 194:1021–1030
doi: 10.4049/jimmunol.1400106
pubmed: 25539811
Rialas CM, Weeks B, Cadet P, Goumon Y, Stefano GB (2000) Nociceptin, endomorphin-1 and-2 do not interact with invertebrate immune and neural mu(3) opiate receptor. Acta Pharmacol Sin 21:516–520
pubmed: 11360685
Ridnour LA, Windhausen AN, Isenberg JS, Yeung N, Thomas DD, Vitek MP, Roberts DD, Wink DA (2007) Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci U S A 104:16898–16903
doi: 10.1073/pnas.0702761104
pubmed: 17942699
pmcid: 2040425
Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A (2009) Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep 21:1323–1333
pubmed: 19360311
Roy S, Cain KJ, Chapin RB, Charboneau RG, Barke RA (1998) Morphine modulates NF kappa B activation in macrophages. Biochem Biophys Res Commun 245:392–396
doi: 10.1006/bbrc.1998.8415
pubmed: 9571161
Sagar S, Sorbi D, Arbeit LA, Singhal PC (1994) Morphine modulates 72-Kda matrix metalloproteinase. Am J Phys 267:F654–F659
Sato H, Seiki M (1993) Regulatory mechanism of 92-Kda type-iv collagenase gene-expression which is associated with invasiveness of tumor-cells. Oncogene 8:395–405
pubmed: 8426746
Sawada M, Ichinose M, Stefano GB (1997) Nitric oxide inhibits the dopamine-induced K+ current via guanylate cyclase in Aplysia neurons. J Neurosci Res 50:450–456
doi: 10.1002/(SICI)1097-4547(19971101)50:3<450::AID-JNR11>3.0.CO;2-A
pubmed: 9364330
Schmitz R (1985) Friedrich Wilhelm Serturner and the discovery of morphine. Pharm Hist 27:61–74
pubmed: 11611724
Schutze S, Wiegmann K, Machleidt T, Kronke M (1995) TNF-induced activation of NF-kappa B. Immunobiology 193:193–203
doi: 10.1016/S0171-2985(11)80543-7
pubmed: 8530143
Sekhon BS (2010) Matrix metalloproteinases-an overview. Res Rep Biol 2010(1):1–20
Sekkai D, Aillet F, Israel N, Lepoivre M (1998) Inhibition of NF-kappaB and HIV-1 long terminal repeat transcriptional activation by inducible nitric oxide synthase 2 activity. J Biol Chem 273:3895–3900
doi: 10.1074/jbc.273.7.3895
pubmed: 9461573
Shariftabrizi A, Nifli AP, Ansari M, Saadat F, Ebrahimkhani MR, Alizadeh N, Nasseh A, Alexaki VI, Dehpour AR, Castanas E, Khorramizadeh MR (2006) Matrix metalloproteinase 2 secretion in WEHI 164 fibrosarcoma cells is nitric oxide-related and modified by morphine. Eur J Pharmacol 530:33–39
doi: 10.1016/j.ejphar.2005.11.043
pubmed: 16386243
Shimomura K, Kamata O, Ueki S, Ida S, Oguri K, Yoshimura H, Tsukamoto H (1971) Analgesic effect of morphine glucuronides. Tohoku J Exp Med 105:45–52
doi: 10.1620/tjem.105.45
pubmed: 5140097
Shin WS, Hong YH, Peng HB, De Caterina R, Libby P, Liao JK (1996) Nitric oxide attenuates vascular smooth muscle cell activation by interferon-gamma. The role of constitutive NF-kappa B activity. J Biol Chem 271:11317–11324
doi: 10.1074/jbc.271.19.11317
pubmed: 8626684
Shin CY, Lee WJ, Choi JW, Choi MS, Ryu JR, Oh SJ, Cheong JH, Choi EY, Ko KH (2007) Down-regulation of matrix metalloproteinase-9 expression by nitric oxide in lipopolysaccharide-stimulated rat primary astrocytes. Nitric Oxide 16:425–432
doi: 10.1016/j.niox.2007.03.004
pubmed: 17452115
Sinha I, Hannawa KK, Ailawadi G, Woodrum DT, Ford JW, Henke PK, Stanley JC, Eagleton MJ, Upchurch GR Jr (2006) The nitric oxide donor DETA-NONOate decreases matrix metalloproteinase-9 expression and activity in rat aortic smooth muscle and abdominal aortic explants. Ann Vasc Surg 20:92–98
doi: 10.1007/s10016-005-9429-1
pubmed: 16378139
Stamenkovic I (2003) Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200:448–464
doi: 10.1002/path.1400
pubmed: 12845612
Stefano GB, Hartman A, Bilfinger TV, Magazine HI, Liu Y, Casares F, Goligorsky MS (1995) Presence of the mu(3) opiate receptor in endothelial cells - coupling to nitric oxide production and vasodilation. J Biol Chem 270:30290–30293
doi: 10.1074/jbc.270.51.30290
pubmed: 8530450
Stefano GB, Scharrer B, Smith EM, Hughes TK Jr, Magazine HI, Bilfinger TV, Hartman AR, Fricchione GL, Liu Y, Makman MH (1996) Opioid and opiate immunoregulatory processes. Crit Rev Immunol 16:109–144
doi: 10.1615/CritRevImmunol.v16.i2.10
pubmed: 8879941
Stefano GB, Salzet B, Rialas CM, Pope M, Kustka A, Neenan K, Pryor S, Salzet M (1997) Morphine- and anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release. Brain Res 763:63–68
doi: 10.1016/S0006-8993(97)00403-4
pubmed: 9272829
Stefano GB, Salzet M, Bilfinger TV (1998) Long-term exposure of human blood vessels to HIV gp120, morphine, and anandamide increases endothelial adhesion of monocytes: uncoupling of nitric oxide release. J Cardiovasc Pharmacol 31:862–868
doi: 10.1097/00005344-199806000-00009
pubmed: 9641470
Stefano GB, Kream RM, Mantione KJ, Sheehan M, Cadet P, Zhu W, Bilfinger TV, Esch T (2008) Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene expression: implications for cancer biology. Semin Cancer Biol 18:199–210
doi: 10.1016/j.semcancer.2007.12.003
pubmed: 18203618
Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM, DeClerck YA (2012) Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 72:2473–2480
doi: 10.1158/0008-5472.CAN-12-0122
pubmed: 22414581
pmcid: 3653596
Taylor DA, Fleming WW (2001) Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. J Pharmacol Exp Ther 297:11–18
pubmed: 11259522
Thirlwell MP, Sloan PA, Maroun JA, Boos GJ, Besner JG, Stewart JH, Mount BM (1989) Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 63:2275–2283
doi: 10.1002/1097-0142(19890601)63:11<2275::AID-CNCR2820631136>3.0.CO;2-4
pubmed: 2720576
van Hinsbergh VW, Engelse MA, Quax PH (2006) Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 26:716–728
doi: 10.1161/01.ATV.0000209518.58252.17
pubmed: 16469948
Vandooren J, Van den Steen PE, Opdenakker G (2013) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol 48:222–272
doi: 10.3109/10409238.2013.770819
pubmed: 23547785
pmcid: 23547785
Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99:157–166
doi: 10.1002/ijc.10329
pubmed: 11979428
Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases - structure, function, and biochemistry. Circ Res 92:827–839
doi: 10.1161/01.RES.0000070112.80711.3D
pubmed: 12730128
pmcid: 12730128
Wang J, Barke RA, Charboneau R, Loh HH, Roy S (2003) Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J Biol Chem 278:37622–37631
doi: 10.1074/jbc.M301224200
pubmed: 12842891
Wang J, Barke RA, Charboneau R, Roy S (2005) Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J Immunol 174:426–434
doi: 10.4049/jimmunol.174.1.426
pubmed: 15611267
Welters ID, Fimiani C, Bilfinger TV, Stefano GB (2000a) NF-kappaB, nitric oxide and opiate signaling. Med Hypotheses 54:263–268
doi: 10.1054/mehy.1999.0032
pubmed: 10790762
Welters ID, Menzebach A, Goumon Y, Cadet P, Menges T, Hughes TK, Hempelmann G, Stefano GB (2000b) Morphine inhibits NF-kappaB nuclear binding in human neutrophils and monocytes by a nitric oxide-dependent mechanism. Anesthesiology 92:1677–1684
doi: 10.1097/00000542-200006000-00027
pubmed: 10839919
Widel MS, Widel M (2006) Mechanisms of metastasis and molecular markers of malignant tumor progression. I. Colorectal cancer. Postepy Hig Med Dosw (Online) 60:453–470
Wink DA, Hines HB, Cheng RY, Switzer CH, Flores-Santana W, Vitek MP, Ridnour LA, Colton CA (2011) Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol 89:873–891
doi: 10.1189/jlb.1010550
pubmed: 21233414
pmcid: 3100761
Xie N, Khabbazi S, Nassar ZD, Gregory K, Vithanage T, Anand-Apte B, Cabot PJ, Sturgess D, Shaw PN, Parat MO (2017) Morphine alters the circulating proteolytic profile in mice: functional consequences on cellular migration and invasion. FASEB J 31:5208–5216
doi: 10.1096/fj.201700546R
pubmed: 28784632
pmcid: 5690391
Yabluchanskiy A, Ma YG, Iyer RP, Hall ME, Lindsey ML (2013) Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology 28:391–403
doi: 10.1152/physiol.00029.2013
pubmed: 24186934
pmcid: 3858212
Ye RD (2001a) Regulation of nuclear factor kappa B activation by G-protein-coupled receptors. J Leukoc Biol 70:839–848
pubmed: 11739545
Ye RD (2001b) Regulation of nuclear factor kappaB activation by G-protein-coupled receptors. J Leukoc Biol 70:839–848
pubmed: 11739545
Zouki C, Jozsef L, Ouellet S, Paquette Y, Filep JG (2001) Peroxynitrite mediates cytokine-induced IL-8 gene expression and production by human leukocytes. J Leukoc Biol 69:815–824
pubmed: 11358991